Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: Results of double blind Phase II clinical trial

Clinical and Experimental Immunology

Volumn 181, Issue 2, 2015, Pages 362-372

  Israeli, E ^a   Goldin, E ^b   Fishman, S ^c   Konikoff, F ^d   Lavy, A ^e   Chowers, Y ^f   Melzer, E ^g   Lahat, A ^h   Mahamid, M ⁱ   Shirin, H ^j   Nussinson, E ^k   Segol, O ^l   Ben Ya'acov, A ^a   Shabbat, Y ^a   Ilan, Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g KAPLAN MEDICAL CENTER   (Israel)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ Israel   (Israel)

^j ASSAF HAROFEH MEDICAL CENTER   (Israel)

^k HAEMEK MEDICAL CENTER   (Israel)

^l CARMEL MEDICAL CENTER   (Israel)

more..

Author keywords

6 mercaptopurine; Crohn's disease; Gut immune system; Oral therapy

Indexed keywords

MERCAPTOPURINE; PADGEM PROTEIN; ANTIMETABOLITE; DELAYED RELEASE FORMULATION; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GASTROINTESTINAL AGENT;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CELL ADHESION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROSSOVER PROCEDURE; DECREASED APPETITE; DELAYED RELEASE FORMULATION; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE; T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER ABDOMINAL PAIN; ADMINISTRATION AND DOSAGE; ADOLESCENT; ADVERSE EFFECTS; AGED; BIOAVAILABILITY; CLINICAL TRIAL; DRUG EFFECTS; GASTROINTESTINAL TRACT; IMMUNOLOGY; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHARMACOKINETICS; QUESTIONNAIRE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMETABOLITES; BIOLOGICAL AVAILABILITY; CELL ADHESION; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84947917149     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12640     Document Type: Article

References (30)

1. Waters OR, Lawrance IC. Understanding the use of immunosuppressive agents in the clinical management of IBD. Curr Drug Targets 2011; 12:1364-71.
2. Bokkerink JP, Stet EH, De Abreu RA et al. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 1993; 45:1455-63.
3. Ebbesen MS, Nersting J, Jacobsen JH et al. Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol 2013; 53:670-4.
4. Ben-Horin S, Goldstein I, Fudim E et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 2009; 58:396-403.
5. Tiede I, Fritz G, Strand S et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133-45.
6. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2013; 4:CD000545.
7. Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013; 145:758-65, e2; quiz e14-5.
8. Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127:723-9.
9. Mate-Jimenez J, Hermida C, Cantero-Perona J et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12:1227-33.
10. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895-902.
11. Gilissen LP, Wong DR, Engels LG et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 2012; 6:698-707.
12. Ilan Y. Oral tolerance: can we make it work? Hum Immunol 2009; 70:768-76.
13. Mizrahi M, Ilan Y. The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des 2009; 15:1191-202.
14. Weiner HL, da Cunha AP, Quintana F et al. Oral tolerance. Immunol Rev 2011; 241:241-59.
15. Bastida G, Nos P, Aguas M et al. The effects of thiopurine therapy on health-related quality of life in inflammatory bowel disease patients. BMC Gastroenterol 2010; 10:26.
16. Kasirer Y, Mevorach R, Renbaum P et al. Thiopurine S-methyltransferase (TPMT) activity is better determined by biochemical assay versus genotyping in the Jewish population. Dig Dis Sci 2014; 59:1207-12.
17. Margalit M, Israeli E, Shibolet O et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006; 101:561-8.
18. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26:987-1003.
19. Kennedy NA, Rhatigan E, Arnott ID et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 2013; 38:1255-66.
20. Castro-Sanchez P, Martin-Villa JM. Gut immune system and oral tolerance. Br J Nutr 2013; 109 (Suppl. 2):S3-11.
21. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204:33-9.
22. Wu HY, Maron R, Tukpah AM et al. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol 2010; 185:3401-7.
23. da Cunha AP, Weiner HL. Induction of immunological tolerance by oral anti-CD3. Clin Dev Immunol 2012; 2012:425021.
24. Cassani B, Villablanca EJ, Quintana FJ et al. Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology 2011; 141:2109-18.
25. Peron JP, Yang K, Chen ML et al. Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. J Neuroimmunol 2010; 227:10-7.
26. Ochi H, Abraham M, Ishikawa H et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci 2008; 274:9-12.
27. Ishikawa H, Ochi H, Chen ML et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007; 56:2103-9.
28. Israeli E, Ilan Y. Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease. Therap Adv Gastroenterol 2010; 3:23-30.
29. Schurmann GM, Bishop AE, Facer P et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36:411-8.
30. Khazen D, Jendoubi-Ayed S, Aleya WB et al. Polymorphism in ICAM-1, PECAM-1, E-selectin, and L-selectin genes in Tunisian patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21:167-75.